Posts Tagged With 'salute'

How to feel better with a ‘trick’ 2017

Come star meglio con un "trucco" edizione 2017How to feel better with a 'trick' 2017

“How to feel better with a ‘trick’” 2017

For the eighth consecutive year WALCE proposes make-up sessions dedicated to women undergoing chemotherapy, radiotherapy or biological therapies.

Posted by admin m d, y No Comments »
Read More

(Italiano) In cucina con WALCE | IX edizione

In cucina con WALCE | IX edizione

Posted by press m d, y No Comments »
Read More

How to feel better with a ‘trick’ 2016

Come star meglio con un "trucco" edizione 2016How to feel better with a 'trick' 2016

“How to feel better with a ‘trick’” 2016

For the seventh consecutive year WALCE proposes make-up sessions dedicated to women undergoing chemotherapy, radiotherapy or biological therapies. 

Posted by press m d, y No Comments »
Read More

NEWS

NEWSNEWSNEWS

“Living With Squamous Cell Lung Cancer: A Guide for Patients” (PDF)

A new educational booklet, that provides specific information on squamous cell lung cancer to patients and their caregivers, with a focus on the advanced stage of this cancer, is available.

August 1, #WorldLungCancerDay | IASLC.org – International Association for the Study of Lung Cancer

“Lung Cancer Screening: Beneficial for Certain Populations but Not Without Controversy” | The ASCO Post.com – Mon. 25 July 2016

“As Low-Dose CT Screening Moves Into the Clinic, Implementation Issues Move Up on the Agenda” | The ASCO Post.com – Mon. 25 July 2016

“Do picture warnings on cigarettes increase quit attempts?” | medicalnewstoday.com – Mon. 6 June 2016

__________________________________________________________________________

Press release: Lung Cancer White Paper launched

Brussels, 10 November: A White Paper aimed at tackling unnecessary deaths caused by lung cancer was launched today in the European Parliament (Tuesday, 10 November) and aims to promote greater access to innovative treatment and more efficient organisation of research.

The authors, the European Alliance for Personalised Medicine (EAPM), say that lung cancer patients urgently need action at the highest level. The document is a direct appeal to EU and Member State policymakers, legislators and regulators.

EAPM writes that improvements will “depend primarily on greater collaboration between Member States and across the healthcare sector. The collaboration should include patients, caregivers and patient organisations, who have an indispensable contribution to make”.

Lung cancer is the biggest global killer of all cancers. Fewer than half of newly diagnosed sufferers live beyond a year, with only 16 percent surviving for five years.

It is such a huge killer partly because it is harder to detect in its early stages. By the time a person begins to notice symptoms, it has often spread to other parts of the body and is, therefore, difficult to treat.

The majority of lung cancers in both sexes are caused by smoking, but about 15 percent are not, and the majority of those non-smokers are women, mostly young women.

Lung cancer in women has increased by a staggering 600% over the past 30 years. Today, more are killed each year by lung cancer than they are by breast, ovarian and uterine cancer combined.

Various theories have been posited for this (estrogen as a tumour promoter, is one example) but, put simply, scientists are just not sure.

The Paper adds: “It is clear that physicians need more effective ways to detect and target these cancers. “European Respiratory Society, lung cancer expert Prof. Jean-Paul Sculier, said: “The battle against lung cancer is lagging behind, for example, the fight against breast cancer. One reason is a general lack of funding for research. More research is desperately needed. Another reason is a relative lack of patient advocacy because so many patients die.”

Gordon McVie, EAPM Secretary, said: “More effort is needed in prevention. Public awareness of the disease and the risk factors should be developed, particularly among younger people, women and front-line healthcare professionals.”

Stefania Vallone, from Women Against Lung Cancer, said: “Many citizens are asking: ‘Why does Europe matter? How does Europe help us?’ In the era of personalised medicine, the EU can help in many ways. “Personalised medicine starts with you and me. It’s all about empowering the patient and giving the right treatment to the right one at the right time – in our case for the lung cancer patients. Sound simple? Well, it isn’t, for a variety of reasons, but the concept is already starting to revolutionise medicine and the way treatment is delivered.”

The White Paper notes that “understanding a new diagnosis is frightening and, because treatments are moving so fast due to developments in science, often confusing. Patients need to realise that treatment strategies will depend on the type of lung cancer, what stage it has reached, their general state of health and more. Add to this the treatment options of surgery, radiation therapy, chemotherapy and established or experimental targeted drugs, plus the various possible side-effects and it becomes a minefield”.

“Healthcare workers must play a vital role in empowering the patient to allow him or her to fully understand the circumstances and make choices,” it adds.

With the increased knowledge of the human genome, physicians can analyse a patient’s genetic make-up —with careful consideration to the tumour cells, which can be unique — and target subsequent therapy to treat the individual patient and the individual tumour.

EAPM says personalised medicine allows scientists to investigate a tumour and try to identify genes to predict for drug sensitivity, or genes that may possibly predict patients who will do better and need no further treatment, or those who might benefit from further treatment. In the future, more and more treatment decisions will be based upon the molecular characteristics of an individual tumour. More research could lead to identifying lung cancer earlier, which would increase the cure rates immensely.

Denis Horgan, EAPM executive director, said: “Personalised medicine for patients with non-small-cell lung cancer is already here. For example, pathologists can perform the most complete and accurate sub-typing of tumours possible. “Next-generation sequencing looks set to allow extensive genetic analysis of single samples, although various technical, logistical and ethical problems – Big Data and data protection, for example – need to be solved.”

“Legislators have a huge role to play here, without a doubt,” Cristian Busoi MEP added.

Regine Deniel Ihlen, from Lung Cancer Europe summed it up, saying: “This is crunch time for Europe. The clock is ticking for patients. But there is time. Time that allows us to put the patients at the centre of their own care but it also means prioritisation is the order of the day. “Better health for citizens and patients is essential to Europe’s prosperity. We cannot grow without healthier citizens that can contribute to the Member Sate and the EU project.”

Among the White Paper’s ‘asks’ are the need for an acknowledgement that lung cancer is one of Europe’s biggest killers and that the European Union can play an important role in helping to tackle the disease.

It adds that the EU should put guidelines in place that will allow Member States to set-up quality assured early detection programmes for lung cancer, and that there is a need for increased public-private partnerships, such as IMI II. The Paper also calls for increased collaboration between pharmaceutical researchers to find the best treatments for patients, which will reduce the cost burden for individual companies in developing treatment.

Finally, it says: “Member States and the EU institutions should act together to overcome the barriers to innovation, including recognising the real value of new treatments and making access to them easier, boosting research across Europe, and including all stakeholders – and particularly patients – in policy formation.”

Press release: Lung Cancer White Paper launched (PDF)

LuCE-EU-Policy-Position-Paper 2015 (PDF)

__________________________________________________________________________

Confronting America’s Smoking Pandemic, Part 1: 1939-1966 | See more at: www.cancernetwork.com

__________________________________________________________________________

ABRAXANE® Approved by European Commission for First-Line Treatment of Patients with Non-Small Cell Lung Cancer (PDF)

__________________________________________________________________________

MEDIA RELEASE – Novartis lung cancer drug Zykadia® recommended for EU approval in patients with ALK+ NSCLC previously treated with crizotinib (PDF)

__________________________________________________________________________

PRESS RELEASE – Celgene Receives Positive CHMP Opinion for ABRAXANE® for First-Line Treatment of Patients with Non-Small Cell Lung Cancer (PDF)

__________________________________________________________________________

PRESS RELEASE VARGATEF® (nintedanib*)

Ingelheim, Germany, (27 November 2014) – Today Boehringer Ingelheim announced that the European Commission has granted EU marketing authorisation for VARGATEF® (nintedanib*), valid for the 28 countries within the EU. VARGATEF® in combination with docetaxel is indicated for use in adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology, after first-line chemotherapy.

“The approval of nintedanib offers a much needed new treatment option for adult lung cancer patients with advanced adenocarcinoma in the second-line setting,” commented PD. Dr Martin Reck, Head of Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Germany and lead investigator of the LUME-Lung 1 trial. “The clinical data has shown that patients receiving nintedanib plus docetaxel experienced over one year overall survival with no further compromise to their quality of life, compared to docetaxel alone.”

Adenocarcinoma is the most common type of lung cancer and the majority of patients are diagnosed in an advanced stage.2 Most patients will experience disease progression during or after first-line chemotherapy and there is a significant unmet need for new, effective second-line treatments.3 “We are delighted by the European Commission’s decision to approve VARGATEF® in the EU and feel extremely proud that our long standing commitment to oncology research and development has brought a new option to lung cancer patients with this specific type of disease,” said Professor Klaus Dugi, Chief Medical Officer, Boehringer Ingelheim. “The approval of VARGATEF® expands our oncology portfolio, following last year’s approval of GIOTRIF® (afatinib) for another specific type of lung cancer. In the idiopathic pulmonary fibrosis indication, nintedanib has recently been approved by the U.S. FDA.”

The approval of nintedanib*, a triple angiokinase inhibitor, is based on the outcomes of the LUME-Lung 1 clinical trial which enrolled 1,314 patients with NSCLC, after first-line chemotherapy.1 Data from the study, published in Lancet Oncology (Feb 2014), demonstrated that compared to docetaxel alone, nintedanib* when added to docetaxel significantly extended median overall survival from 10.3 to 12.6 months (p=0.0359; HR: 0.83) for patients with adenocarcinoma, with a quarter of patients surviving for two years or more (survival at 24 months – nintedanib* plus docetaxel, 25.7% of patients vs. placebo plus docetaxel, 19.1% of patients, p=0.0359; HR: 0.83).1 Nintedanib* demonstrated a manageable adverse event profile without further compromising patients’ overall health-related quality of life.

Adding nintedanib* to docetaxel did not significantly increase discontinuation rates, compared to docetaxel alone.1 Nintedanib* is an oral, twice-daily treatment and is the second approved compound in the Boehringer Ingelheim oncology portfolio. GIOTRIF® (afatinib**) was the first oncology drug from the portfolio to be approved to treat non-small cell lung cancer patients with distinct types of EGFR-mutation positive NSCLC.

References

  1. Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014;15:143–55.
  2. Howlader N, et al. SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER website, April 2014.
  3. Hilberg F, Roth GJ, Krssak M, et al. BIBF1120: triple angiokinase inhibitor with sustained receptor blockade and good anti-tumor efficacy. Cancer Res 2008;68: 4774-82

PRESS RELEASE VARGATEF® (nintedanib*) (PDF)

__________________________________________________________________________

Lung Cancer: We’re Listening – helping us to better understand life with lung cancer

Lung Cancer: We’re Listening is a survey that uses pictures to allow lung cancer patients and family members from around the world to express, share and compare experiences. The information gathered from this survey will be used to improve lung cancer awareness and support services.

If you have lung cancer, or care for a loved one with lung cancer, please click on the link below to complete this short survey and tell us about some of the challenges you may be facing right now– it only takes a few minutes.

Go to http://www.wearelistening.info/ to share your experience of life with lung cancer

__________________________________________________________________________

“Widower re-creates his wedding day photos with three-year-old daughter”: read the article

__________________________________________________________________________

27th September 2013, Amsterdam: New European association for lung cancer patients launched today

Press Release (Pdf)

__________________________________________________________________________

Bonnie J. Addario starring at The Steve Harvey Show in USA

__________________________________________________________________________

From VITAL OPTIONS lNTERNATIONAL Newsletter – Summer 2013: NEW Videos Released From ASCO 2013

__________________________________________________________________________

Breaking News: The Lung Times Newsletter

__________________________________________________________________________

Vital Options International – Newsletter – May, 2013

__________________________________________________________________________

11th Annual National Young Adult Cancer Awareness Week April 1-7, 2013

__________________________________________________________________________

Lung cancer ‘overtaking breast cancer in European women’

http://www.bbc.co.uk/news/health

__________________________________________________________________________

Pfizer’s XALKORI® receives Conditional Marketing Authorization from the European Commission for the treatment of adults with previously treated ALK-Positive Advanced Non-Small Cell Lung Cancer In The EU. Press Release

__________________________________________________________________________

News from American Society of Clinical Oncology (ASCO)

ASCO: Afatinib Improves PFS, Quality of Life in EGFR Mutation-Positive Lung Cancer

http://www.cancernetwork.com/conference-reports/asco2012/lung-cancer

European Medicines Agency boosts EU transparency with online publication of suspected side effect reports

http://www.ema.europa.eu/ema

Best practices on civic participation on active ageing policies

Active Citizenship decided to dedicate a project to the 2012 European Year for Active Ageing and Solidarity between Generations. “Best practices on civic participation on Active Ageing policies” directly falls into the 6th European Patients’ Rights Day, which will be celebrated as every year the 18th of April. This fundamental project will be concluded through the Conference “Active Ageing citizens at the center of EU health policy”, to be held in Brussels the 15th – 16th May 2012.

www.activecitizenship.net/primo-piano/59-best-practices-on-active-ageing-citizens-at-the-center-of-eu-health-policy.html

Newsletter from National Lung Cancer Partnership.

National Radon Action Month: January is National Radon Action Month…

Posted by press m d, y No Comments »
Read More